From one-stop testing and treatment sites to boosting research and surveillance, Biden administration health officials expanded on the COVID-19 plan the president announced in his State of the Union address Tuesday night, but the plan will require additional funding from Congress.
The day after President Joe Biden announced a new phase in the country’s fight against COVID-19, the administration’s’ top health officials outlined more details about the plan and said guidance about masking on public travel would be reevaluated later this month.
The National COVID-19 Preparedness Plan focuses on vaccines and treatments, preventing shutdowns, preparing for new variants, and continuing to assist in global vaccination efforts.
Hundreds of one-stop sites will open this month in local pharmacies, community health centers, nursing homes, and veteran's health centers stocked with COVID-19 tests and the antiviral drug from Pfizer, said Jeff Zients, the White House Coronavirus Response Coordinator. If an individual tests positive, they would be supplied with a 5-day course of Pfizer’s nirmatrelvir tablets and ritonavir tablets, sold together as Paxlovid, which must be taken within the first 5 days of symptoms.
“We're launching the ‘Test to Treat’ initiative so people can get tested at a pharmacy, and if they’re positive, receive antiviral pills on the spot at no cost,” Biden said Tuesday night. The US has a contract with Pfizer for the pills; Zients said 1 million courses would be available this month and 2 million next month and that 20 million courses have been ordered. The pills are 90% effective at preventing hospitalizations.
The media briefing with Zients; Anthony Fauci, MD, the head of the National Institute of Allergy and Infectious Diseases and the president’s chief medical advisor; HHS Secretary Xavier Becerra; and CDC Director Rochelle Walensky, MD, reviewed how the administration envisions the country will move beyond the crisis phase of the pandemic, while simultaneously being prepared for new variants.
Asked if they were prepared to lift remaining mask requirements for public travel, officials said they would reexamine both later this month. Last Friday, the CDC released new guidance that said most healthy adults living in areas where there is a low or medium threat of COVID-19 overwhelming hospitals can remove masks in indoor settings.
Asked to provide a funding amount to fulfill all aspects of the president’s National COVID-19 Preparedness Plan, Zients said the amount is still being finalized.
Becerra said the president’s pandemic response would become a permanent part of HHS, organized under Dawn O’Connell, the assistant secretary for preparedness and response.
If Congress agrees to fully fund the plan, HHS would work to establish “centers of excellence” to care for patients with long COVID, Becerra said. In addition, HHS will seek to support “people dealing with mental health–related challenges, including an expanded program to prevent job burnout and support the mental well-being of our nation's health care workforce. We want every frontline essential health care worker to know we’re with you.”
Other parts of the president's plan include:
In addition, Facui said there are some candidates for a pan–SARS-CoV-2 vaccine in preclinical or phase 1 trials.
Asked if the federal public health emergency might be lifted, Walensky said it is reevaluated every 4 to 8 weeks and has been throughout the pandemic, now more than 2 years old worldwide.
Fauci said the daily caseload is about 68,000 a day. In January, during the Omicron surge, it was about 800,000 a day. Almost a million Americans have died from the virus.
As part of the plan, the Surgeon General's office will issue a request for information from researchers and organizations to understand more about the impact of COVID-19 misinformation, including quality of care, health decisions, health costs, worker morale and safety, and the implications for future pandemics.
Zients said 216 million Americans are vaccinated against the virus and 2 of 3 eligible adults have received a booster.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More